Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

IGC

IGC Pharma Inc

Apr 24 • 04:00PM ET

0.3372

-0.0025 -0.74 %

Healthcare • Biotechnology • USA • Nano • AMEX

Peers: CGC TLRY CRON ACB TVRD RVNC GNLN DFTX PHGE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.06	Insider Own	23.10%	Shs Outstand	95.04M	Perf Week	0.39%
Market Cap	33.31M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	75.97M	Perf Month	28.70%
Enterprise Value	32.51M	PEG	-	EPS next Q	-0.03	Inst Own	4.84%	Short Float	1.15%	Perf Quarter	15.88%
Income	-5.34M	P/S	27.76	EPS this Y	-	Inst Trans	-1.00%	Short Ratio	0.83	Perf Half Y	-11.12%
Sales	1.20M	P/B	4.32	EPS next Y	-	ROA	-56.87%	Short Interest	0.87M	Perf YTD	19.83%
Book/sh	0.08	P/C	35.44	EPS next 5Y	-	ROE	-78.10%	52W High	0.50 -32.36%	Perf Year	7.46%
Cash/sh	0.01	P/FCF	-	EPS past 3/5Y	32.33% 12.85%	ROIC	-70.71%	52W Low	0.24 39.34%	Perf 3Y	0.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	47.38% -20.77%	Gross Margin	3.00%	Volatility	10.00% 7.45%	Perf 5Y	-78.93%
Dividend TTM	-	EV/Sales	27.09	EPS Y/Y TTM	49.51%	Oper. Margin	-763.72%	ATR (14)	0.02	Perf 10Y	-16.14%
Dividend Ex-Date	-	Quick Ratio	0.53	Sales Y/Y TTM	-2.99%	Profit Margin	-445.62%	RSI (14)	64.42	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.83	EPS Q/Q	67.80%	SMA20	12.75%	Beta	0.54	Target Price	4.12
Payout	-	Debt/Eq	0.02	Sales Q/Q	36.19%	SMA50	18.49%	Rel Volume	0.39	Prev Close	0.34
Employees	70	LT Debt/Eq	0.02	Earnings	Mar 19 BMO	SMA200	0.09%	Avg Volume	1.06M	Price	0.34
IPO	Apr 13, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	50.00% 21.70%	Trades		Volume	410,563	Change	-0.74%

Apr-22-26 08:30AM	IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion (ACCESSWIRE) +10.17%
Apr-20-26 08:30AM	IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia (ACCESSWIRE) -5.03%
Apr-14-26 08:30AM	IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout (ACCESSWIRE)
Apr-08-26 12:45PM	Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts (ACCESSWIRE)
Apr-07-26 08:00AM	IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease (ACCESSWIRE)
08:00AM	Loading…
Mar-30-26 08:00AM	IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness (ACCESSWIRE)
Mar-19-26 09:00AM	IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 (ACCESSWIRE)
Mar-18-26 09:00AM	IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 (ACCESSWIRE)
Mar-05-26 07:05AM	Merck KGaA (MKKGY) Lags Q4 Earnings Estimates (Zacks)
Feb-26-26 08:30AM	IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research (ACCESSWIRE)
Feb-24-26 08:49AM	IGC Pharma expands Phase 2 CALMA trial with new clinical site (TipRanks)
08:30AM	IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets (ACCESSWIRE)
Feb-23-26 08:30AM	IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial (ACCESSWIRE)
Feb-17-26 08:30AM	IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances (ACCESSWIRE)
Feb-12-26 08:30AM	IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets (ACCESSWIRE)
08:30AM	Loading…
Feb-10-26 08:30AM	IGC Pharma Announces Equity Research Update by Alliance Global Partners (ACCESSWIRE)
Feb-09-26 08:30AM	IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center (ACCESSWIRE)
Feb-02-26 08:30AM	IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation (ACCESSWIRE)
Jan-22-26 09:00AM	IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York (ACCESSWIRE) +7.31%
Jan-12-26 09:00AM	IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia (ACCESSWIRE)
Jan-06-26 08:00AM	IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability (ACCESSWIRE)
Jan-05-26 09:00AM	IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial (ACCESSWIRE)
Dec-19-25 09:00AM	IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum (ACCESSWIRE) -10.74%
Dec-15-25 09:00AM	IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines (ACCESSWIRE)
Dec-13-25 11:15AM	Trump expected to sign EO to reclassify marijuana as soon as Monday, CNBC says (TipRanks)
Dec-10-25 09:00AM	IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." (ACCESSWIRE) +14.77%
Dec-09-25 09:00AM	IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial (ACCESSWIRE)
Dec-02-25 09:00AM	IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease (ACCESSWIRE)
Nov-25-25 09:00AM	IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends (ACCESSWIRE)
Nov-17-25 06:00PM	IGC Pharma Inc (IGC) Q2 2026 Earnings Call Highlights: Strategic Advances and Financial Maneuvers (GuruFocus.com) -5.03%
08:30AM	Loading…
08:30AM	IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital (ACCESSWIRE)
Nov-14-25 05:30PM	IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Nov-13-25 05:20PM	Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
09:00AM	USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders (ACCESSWIRE)
Nov-12-25 05:15PM	Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -5.35%
Nov-10-25 05:20PM	Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates (Zacks)
Nov-06-25 07:10AM	Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-03-25 08:52AM	IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline (ACCESSWIRE)
Oct-24-25 12:00PM	All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy (Zacks) +7.90%
10:00AM	Best Momentum Stocks to Buy for Oct. 24 (Zacks)
05:17AM	New Strong Buy Stocks for Oct. 24: IGC, ASM and More (Zacks)
Oct-22-25 09:00AM	IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant" (ACCESSWIRE)
Oct-14-25 09:00AM	IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences (ACCESSWIRE) +5.96%
Oct-10-25 07:50PM	IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders (ACCESSWIRE)
Oct-07-25 09:00AM	IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease (ACCESSWIRE)
Sep-29-25 09:00AM	IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial (ACCESSWIRE) +5.61%
Sep-24-25 09:00AM	IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology (ACCESSWIRE)
Sep-22-25 09:00AM	IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial (ACCESSWIRE)
Sep-09-25 09:00AM	IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection (ACCESSWIRE)
Sep-02-25 09:00AM	IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada (ACCESSWIRE)
Aug-28-25 09:00AM	IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome (ACCESSWIRE) -5.87%
Aug-27-25 09:00AM	IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50." (ACCESSWIRE) +15.74%
Aug-25-25 09:00AM	IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City (ACCESSWIRE)
Aug-19-25 09:00AM	IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial (ACCESSWIRE)
Aug-14-25 05:25PM	IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Aug-13-25 05:15PM	Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-12-25 05:20PM	Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates (Zacks)
09:00AM	IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1 (ACCESSWIRE)
Aug-05-25 09:00AM	IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression (ACCESSWIRE)
Jul-23-25 09:00AM	IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025 (ACCESSWIRE)
Jul-21-25 09:00AM	IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards (ACCESSWIRE)
Jul-10-25 03:10PM	IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection (ACCESSWIRE) +13.39%
Jun-30-25 09:00AM	IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation (ACCESSWIRE)
Jun-27-25 05:45PM	IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Jun-23-25 08:30AM	IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon (ACCESSWIRE)
May-30-25 05:25PM	Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.22%
May-22-25 09:30AM	IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market (ACCESSWIRE)
May-12-25 09:30AM	IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting (ACCESSWIRE)
Apr-24-25 09:30AM	IGC Pharma Welcomes Strategic Investment from Advisors (ACCESSWIRE) +6.73%
Apr-09-25 09:35AM	IGC Pharma expands CALMA trial with addition of Butler Hospital Program (TipRanks)
Mar-17-25 09:00AM	IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida (ACCESS Newswire)
Mar-12-25 09:00AM	IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" (ACCESS Newswire) +9.59%
Mar-10-25 09:00AM	IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" (ACCESS Newswire) +6.46%
Mar-04-25 09:00AM	IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection (ACCESS Newswire)
Feb-21-25 09:25AM	IGC Pharma expands Holiby line with Longevity, Renew (TipRanks)
Feb-20-25 09:00AM	IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market (ACCESS Newswire)
Feb-18-25 08:30AM	IGC Pharma Reports Third Quarter Fiscal 2025 Results (ACCESS Newswire)
Feb-11-25 08:30AM	IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM) (ACCESS Newswire)
Jan-28-25 08:30AM	IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease (ACCESS Newswire)
Jan-21-25 08:30AM	IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor (ACCESS Newswire)
Jan-13-25 08:30AM	IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets (ACCESSWIRE)
Jan-08-25 08:30AM	IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy (ACCESSWIRE)
Dec-19-24 07:00PM	IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 (ACCESSWIRE)
Dec-02-24 08:30AM	IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology (ACCESSWIRE)
Nov-25-24 08:30AM	IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment (Business Wire) +5.34%
Nov-14-24 08:30AM	IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline (ACCESSWIRE)
Nov-06-24 08:30AM	IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies (ACCESSWIRE)
Oct-17-24 08:30AM	IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 (ACCESSWIRE)
Oct-03-24 09:00AM	IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge (ACCESSWIRE) -6.10%
Sep-18-24 08:00AM	IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment (Business Wire)
Sep-04-24 08:00AM	IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease (Business Wire)
Aug-26-24 07:00PM	IGC Announces Results of its 2024 Annual Stockholders Meeting (Business Wire)
Aug-22-24 09:00AM	IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease (Business Wire) -7.56%
Aug-20-24 08:00AM	IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist (Business Wire) -7.62%
Aug-08-24 09:30PM	IGC Pharma Reports First Quarter Fiscal 2025 Results (Business Wire)
Jul-18-24 09:00AM	IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target (Business Wire) +5.71%
Jul-09-24 09:10AM	Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile (Business Wire)
Jun-25-24 09:00AM	IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease (Business Wire) -8.10%
Jun-24-24 07:30PM	IGC Reports Financial Results for Fiscal Year Ended March 31, 2024 (Business Wire) -14.65%
Jun-18-24 09:00AM	IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets (Business Wire)

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PRINS RICHARD K	Director	Apr 01 '26	Option Exercise	0.00	170,000	0	1,541,251	Apr 06 04:02 PM
Mukunda Ram	CEO	Apr 01 '26	Option Exercise	0.13	656,410	84,000	4,649,088	Apr 06 04:02 PM
Mukunda Ram	CEO	Apr 01 '26	Option Exercise	0.00	49,999	0	910,751	Apr 06 04:02 PM
Moran James P	Director	Apr 01 '26	Option Exercise	0.00	130,000	0	1,235,735	Apr 06 04:02 PM
GRIMALDI CLAUDIA	PFO	Apr 01 '26	Option Exercise	0.15	238,462	36,000	1,372,714	Apr 06 04:01 PM
Mukunda Ram	CEO	Feb 03 '26	Option Exercise	0.00	50,000	0	860,752	Feb 04 05:31 PM
PRINS RICHARD K	Director	Jan 19 '26	Option Exercise	0.00	100,000	0	1,371,251	Jan 20 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IGC

IGC Pharma Inc

Upgrade your Finviz experience